Consonance Capital CEO Mitchell Blutt is a leader in the field of health care investment and a professor at Weill Cornell Medical College. In addition, Mitchell Blutt has served on the boards of multiple health care research organizations, including the Michael J. Fox Foundation.

1. Mitchell Blutt
The Michael J. Fox Foundation -
Understanding the LRRK2 Gene

2. Introduction
 Consonance Capital CEO Mitchell Blutt is a
leader in the field of health care investment and a
professor at Weill Cornell Medical College. In
addition, Mitchell Blutt has served on the boards
of multiple health care research organizations,
including the Michael J. Fox Foundation.
Popular actor Michael J. Fox was diagnosed with
young-onset Parkinson's disease in 1991. After
making his diagnosis public in 1998, he began to
campaign for expanded research into the
disease. He established the Michael J. Fox
Foundation in 2000, with the goal of improving

3. Michael J. Fox Foundation
 The Foundation is committed to efficiency and
expediency. It works tirelessly to speed up
breakthroughs and expedite patient access to new
therapies and medications. Dedicated to a high-risk,
high-reward method of research, the Foundation has
enjoyed several major victories in its relatively short
history.
One such victory is the improved understanding of
underlying genetic factors. In 2004, researchers
discovered the gene LRRK2, which is now considered
to be the greatest genetic contributor to Parkinson's,
accounting for a significant percentage of cases within
certain ethnic groups. Recent breakthroughs involving
the LRRK2 gene may help scientists learn more about
genetic commonalities between patients, which could